Suppr超能文献

术前化疗可能通过胃癌患者的术后并发症改变复发模式。

Preoperative chemotherapy could modify recurrence patterns through postoperative complications in patients with gastric cancer.

机构信息

Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, 252-0374, Japan.

Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.

出版信息

Langenbecks Arch Surg. 2021 Jun;406(4):1045-1055. doi: 10.1007/s00423-021-02153-5. Epub 2021 Mar 20.

Abstract

PURPOSE

Postoperative infectious complications have a negative impact on survival outcomes in patients with gastric cancer. It is recently reported that preoperative chemotherapy may eliminate this negative impact. This study aimed to confirm whether preoperative chemotherapy can eliminate the negative impact of postoperative infectious complications (IC) on survival outcomes and elucidate the association between postoperative infectious complications and recurrence patterns.

METHODS

We retrospectively reviewed data of 86 patients who received preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by R0 gastrectomy at the Kitasato University between 2006 and 2016. Patients who developed grade II or higher infectious complications during hospitalization were grouped into the IC group, while others were grouped into the non-IC (NIC) group. Survival outcomes and recurrence patterns were analyzed between the two groups.

RESULTS

Infectious complications with Clavien-Dindo classification of grade II or higher were found in 12 patients (14.0%, IC group). The median observational period was 61 months. Overall survival and progression-free survival were similar in the IC and NIC groups. Recurrence occurred in 39 patients. The proportions of peritoneal and lymph node recurrences were not significantly different between the two groups. However, the proportion of distant metastasis in the IC group was significantly higher than that in NIC group (3/4 [75%] vs. 9/35 [17%], p = 0.04).

CONCLUSIONS

Pathological stage after neoadjuvant therapy plays a stronger role in recurrence than postoperative complications. Lymph node and peritoneal metastasis may be suppressed by preoperative chemotherapy.

摘要

目的

术后感染并发症会对胃癌患者的生存结果产生负面影响。最近有报道称,术前化疗可能消除这种负面影响。本研究旨在确认术前化疗是否可以消除术后感染并发症(IC)对生存结果的负面影响,并阐明术后感染并发症与复发模式之间的关系。

方法

我们回顾性分析了 2006 年至 2016 年在北里大学接受多西他赛、顺铂和 S-1 术前化疗后行 R0 胃切除术的 86 例患者的数据。在住院期间发生 II 级或更高等级感染并发症的患者分为感染组(IC 组),其余患者分为非感染组(NIC 组)。分析两组之间的生存结果和复发模式。

结果

12 例(14.0%)患者出现 Clavien-Dindo 分级 II 级或更高的感染并发症(IC 组)。中位观察期为 61 个月。IC 组和 NIC 组的总生存率和无进展生存率相似。39 例患者发生复发。两组腹膜和淋巴结复发的比例无显著差异。然而,IC 组的远处转移比例明显高于 NIC 组(3/4[75%]比 9/35[17%],p=0.04)。

结论

新辅助治疗后的病理分期比术后并发症对复发的影响更大。淋巴结和腹膜转移可能被术前化疗抑制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验